Article

J&J Opens Doxil Rationing Program To New Patients

Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up.

In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.

About 1,000 patients are now receiving Doxil--which treats ovarian and other cancers--through an allocation program that J&J created last year to address a product shortage.

Read the full story: http://hcp.lv/K6a9Bp

Source: Morningstar

Related Videos
Mei Wei, MD.
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Sandra Cueller, PharmD
Ticiana Leal, MD
James Chambers, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo